ORDER XELPROS® EXCLUSIVELY THROUGH THE Xelpros Xpress® PROGRAM

Xelpros®

(latanoprost ophthalmic emulsion) 0.005%

Formulated with LIPIXELLE® TECHNOLOGY



PRESCRIBE YOUR PATIENTS THE POWER OF A BAK-FREE LATANOPROST[1]

XELPROS® is the first and only BAK-free latanoprost delivered with LIPIXELLE®, a novel micelle microemulsion formulation.[1,2]

SCAN TO REQUEST A SAMPLE OF XELPROS

BAK=benzalkonium chloride.

INDICATIONS AND USAGE

XELPROS® (latanoprost ophthalmic emulsion) 0.005% is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

XELPROS is contraindicated in patients with a known hypersensitivity to latanoprost, or any other ingredients in this product.

Please see the additional Important Safety Information throughout and the enclosed Full Prescribing Information.

LEARN MORE INSIDE



Xelpros®
(latanoprost ophthalmic emulsion) 0.005%

Formulated with LIPIXELLE® TECHNOLOGY

Innovative Delivery For Your Patients

LIPIXELLE® technology allows for BAK-free delivery and improved solubility[2]

Following instillation of XELPROS® into the eye[2]:

- LIPIXELLE technology encapsulates latanoprost within polymer/castor oil micelles
- The micelles mix with the tear film
- As the micelles migrate toward the ocular surface, they break apart, releasing latanoprost onto the ocular surface for easier penetration
- Other components of the micelle structure (castor oil, polymer) then supplement both the lipid and aqueous layers of the tear film

SCAN TO LEARN MORE ABOUT THE SAFETY PROFILE OF XELPROS

IMPORTANT SAFETY INFORMATION (CONT'D)

WARNINGS AND PRECAUTIONS

Pigmentation: XELPROS may cause changes to pigmented tissues. The most frequently reported changes are increased pigmentation of the iris, periorbital tissue (eyelid), and eyelashes. Pigmentation is expected to increase as long as XELPROS is administered. After discontinuation of XELPROS, iris pigmentation is likely to be permanent. Patients who receive treatment should be informed of the possibility of increased pigmentation. The long-term effects of increased pigmentation are not known.

Eyelash Changes: XELPROS may gradually change eyelashes and vellus hair in the treated eye, including increased length, thickness, pigmentation, and number of lashes. The changes are usually reversible upon discontinuation of treatment.

Intraocular Inflammation: XELPROS should be used with caution in patients with a history of intraocular inflammation (iritis/uveitis) and should generally not be used in patients with active intraocular inflammation.

Please see additional Important Safety Information throughout and the enclosed Full Prescribing Information.

ORDER XELPROS® EXCLUSIVELY THROUGH THE XelprosXpress® PROGRAM

Visit **XELPROS.com** to Learn More

The Proven IOP-Lowering Power of XELPROS®[1,2,a]

XELPROS demonstrated IOP-lowering power throughout the day (similar to Xalatan®, branded latanoprost)[2]

The most common ocular adverse reactions in clinical trials (incidence ≥5%) for XELPROS were eye pain/stinging, ocular hyperemia, conjunctival hyperemia, eye discharge, growth of eyelashes, and eyelash thickening.[1]

Study CLR-08-01: Peak IOP-lowering effect (mmHg) for XELPROS and Xalatan[2]



In clinical trials, XELPROS demonstrated significant reductions in intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.[1]

The mean IOP-lowering effect was up to 6-8 mmHg in patients with mean baseline IOP of 23-26 mmHg[1]

[a]**STUDY DESIGN**: The efficacy and safety of XELPROS were assessed in 2 randomized, active-controlled (vs Xalatan) clinical trials in patients with open-angle glaucoma or ocular hypertension. Study 1 (CLR-08-01) included 104 patients (53 received XELPROS) with IOP measured in the morning and evening over 4 weeks. Study 2 (CLR-09-12) included 578 patients (289 received XELPROS) with IOP measured at 8:00 AM, 10:00 AM, and 4:00 PM over 12 weeks. XELPROS was dosed once daily in the evening in both trials.[2]

IMPORTANT SAFETY INFORMATION (CONT'D)

WARNINGS AND PRECAUTIONS (CONT'D)

Macular Edema: XELPROS should be used with caution in aphakic patients, in pseudophakic patients with a torn posterior lens capsule, or in patients with known risk factors for macular edema.

Herpetic Keratitis: XELPROS should be used with caution in patients with a history of herpetic keratitis. XELPROS should be avoided in cases of active herpes simplex keratitis because inflammation may be exacerbated.

Bacterial Keratitis: There have been reports of bacterial keratitis associated with the use of multiple-dose containers of topical ophthalmic products.

Use with Contact Lenses: Contact lenses should be removed prior to administration of XELPROS and may be reinserted 15 minutes following administration.

Please see additional Important Safety Information throughout and the enclosed Full Prescribing Information.

Consistent 12-Month Pricing That Your Patients Can Count On Through XELPROS Xpress®

$60
1-month supply*

OR

$115
3-month supply†
A 36% SAVINGS

Xelpros Xpress®

We've made it convenient and hassle-free.
Our pharmacy partners ship XELPROS directly to patients.

- **NO** prior authorization, step edits or coupons needed
- **NO** office staff callbacks required
- **NO** surprises with a low, set price – a 1-month supply of XELPROS for $60* or a 3-month supply for $115†
- **NO** additional charges for uninsured patients – insured and uninsured pay the same

*1 month = 1 bottle.
†Patients must buy a 3-month supply of XELPROS during a single purchase to receive it at this reduced price.

3 EASY WAYS TO START YOUR PATIENTS WITH A SAMPLE TODAY

1 Scan the QR code

OR

2 Visit UseXelpros.com

OR

3 Complete and mail attached pre-paid postcard

IMPORTANT SAFETY INFORMATION (CONT'D)

ADVERSE REACTIONS

The most common ocular adverse reactions in clinical trials (incidence ≥5%) for XELPROS were eye pain/stinging, ocular hyperemia, conjunctival hyperemia, eye discharge, growth of eyelashes, and eyelash thickening.

DRUG INTERACTIONS

Precipitation may occur if drugs containing thimerosal are used concomitantly with XELPROS. If such drugs are used, they should be administered at least 5 minutes apart.

Please see the enclosed Full Prescribing Information.

For physicians practicing in Colorado, please visit xelpros.com/colorado for updated pricing information

References: 1. XELPROS [package insert]. Cranbury, NJ: Sun Pharmaceutical Industries, Inc.; 2018. **2.** Data on file. Cranbury, NJ: Sun Pharmaceutical Industries, Inc.

SUN OPHTHALMICS

PM-US-XPS-0381 10/2022